Athira Pharma Presents Preclinical Data Further Supporting The Therapeutic Potential Of ATH-1105 In Amyotrophic Lateral Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma has presented preclinical data supporting the therapeutic potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS). The data indicates consistent reduction in plasma neurofilament light chain levels and preservation of motor function. The data was presented at the Northeast ALS Consortium meeting.
October 05, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Athira Pharma's preclinical data supports the therapeutic potential of their drug ATH-1105 in treating ALS. This could potentially lead to increased investor interest in the company.
The positive preclinical data for ATH-1105 indicates potential for the drug's success in treating ALS. This could lead to increased investor interest in Athira Pharma, potentially driving up the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100